MyoKardia’s myosin mechanism deconvolution

With preclinical proof of concept that its lead candidate mavacamten acts via two distinct mechanisms to treat cardiomyopathy, MyoKardia Inc. is ready to accelerate a pipeline of preclinical programs that exploit the mechanisms separately for different genetic or phenotypically defined diseases.

At the November American Heart Association meeting, MyoKardia presented data showing that in addition to reducing excessive contractile strength in hypertrophic cardiomyopathy (HCM), mavacamten improves the heart’s ability to relax afterwards. ...